Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study.
Saved in:
| Title: | Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study. |
|---|---|
| Authors: | Brizzi, M. P.1, Fazio, N.2, Ferrero, A.3, Nobili, E.4, Volante, M.5, Tozzi, L.6, D'Avolio, A.7, Milanesi, E.8, Dogliotti, L.1, Berruti, A.1 |
| Source: | Neuroendocrinology. Jul2012 Supplement, Vol. 96, p22-23. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 80169271 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Brizzi%2C+M%2E+P%2E%22">Brizzi, M. P.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Fazio%2C+N%2E%22">Fazio, N.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Ferrero%2C+A%2E%22">Ferrero, A.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Nobili%2C+E%2E%22">Nobili, E.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Volante%2C+M%2E%22">Volante, M.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Tozzi%2C+L%2E%22">Tozzi, L.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22D'Avolio%2C+A%2E%22">D'Avolio, A.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Milanesi%2C+E%2E%22">Milanesi, E.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Dogliotti%2C+L%2E%22">Dogliotti, L.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Berruti%2C+A%2E%22">Berruti, A.</searchLink><relatesTo>1</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Neuroendocrinology%22">Neuroendocrinology</searchLink>. Jul2012 Supplement, Vol. 96, p22-23. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=80169271 |
| RecordInfo | BibRecord: BibEntity: Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: 22 Titles: – TitleFull: Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Brizzi, M. P. – PersonEntity: Name: NameFull: Fazio, N. – PersonEntity: Name: NameFull: Ferrero, A. – PersonEntity: Name: NameFull: Nobili, E. – PersonEntity: Name: NameFull: Volante, M. – PersonEntity: Name: NameFull: Tozzi, L. – PersonEntity: Name: NameFull: D'Avolio, A. – PersonEntity: Name: NameFull: Milanesi, E. – PersonEntity: Name: NameFull: Dogliotti, L. – PersonEntity: Name: NameFull: Berruti, A. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 07 Text: Jul2012 Supplement Type: published Y: 2012 Identifiers: – Type: issn-print Value: 00283835 Numbering: – Type: volume Value: 96 Titles: – TitleFull: Neuroendocrinology Type: main |
| ResultId | 1 |
